Passage Bio remains on track to seek regulatory feedback on a registrational trial design for FTD-GRN in the first half of 2026.

Business Operations | News, how-tos, features, reviews, and videos ...

PHILADELPHIA - Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company with a market capitalization of $24.3 million, reported updated interim data from its Phase 1/2 upliFT-D ...

Find the latest historical data for Cisco Systems, Inc. Common Stock (DE) (CSCO) at Nasdaq.com. View historical data in a monthly, bi-annual, or yearly format.

Enterprise technology news and analysis ...